Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>HEALIOS K.K. is a clinical-stage biotechnology company at the forefront of regenerative medicine in Japan, focusing on high unmet medical needs such as ischemic stroke and Acute Respiratory Distress Syndrome (ARDS).</li>
  <li>The company's lead asset, HLCM051 (MultiStem), is advancing towards late-stage clinical trials. A key potential catalyst is the planned application for conditional approval for ARDS in Japan, which could occur as early as 2025.</li>
  <li>Financially, the company is characterized by significant R&amp;D investment, leading to persistent net losses and negative cash flow. Its future is heavily dependent on clinical trial outcomes, regulatory approvals, and the ability to secure ongoing funding.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  HEALIOS K.K. is a clinical-stage biotechnology company at the forefront of regenerative medicine in Japan, focusing on high unmet medical needs such as ischemic stroke and Acute Respiratory Distress Syndrome (ARDS).
  The company's lead asset, HLCM051 (MultiStem), is advancing towards late-stage clinical trials. A key potential catalyst is the planned application for conditional approval for ARDS in Japan, which could occur as early as 2025.
  Financially, the company is characterized by significant R&amp;D investment, leading to persistent net losses and negative cash flow. Its future is heavily dependent on clinical trial outcomes, regulatory approvals, and the ability to secure ongoing funding.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in margin trading positions of JPX stocks as of Jul 25th. The aggregated net margin trading position is USD15,503m.</li>
<li>We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.</li>
<li>We highlight net margin buy/sell changes in Mitsubishi Heavy Industries, Fast Retailing, Mitsubishi UFJ Financial, Toyota Motor, Lasertec, Sumitomo Mitsui Financial, Marui, Sanrio, Disco, Kawasaki Heavy Industries.</li>
</ul>


We analyzed the changes in margin trading positions of JPX stocks as of Jul 25th. The aggregated net margin trading position is USD15,503m.
We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.
We highlight net margin buy/sell changes in Mitsubishi Heavy Industries, Fast Retailing, Mitsubishi UFJ Financial, Toyota Motor, Lasertec, Sumitomo Mitsui Financial, Marui, Sanrio, Disco, Kawasaki Heavy Industries.


JPX Margin Trading Weekly (Jul 25th): Mitsubishi Heavy Industries, Fast Retailing

Japan

Healios K.K. researches and develops iPSC Regenerative Medicine and Compound Drugs. The company researches for the development of treatment for Age-Related Macular Degeneration.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HEALIOS KK (4593 JP)

Primer: HEALIOS KK (4593 JP) - Dec 2025

HEALIOS K.K. is a clinical-stage biotechnology company at the forefront of regenerative medicine in Japan, focusing on high unmet medical needs...

αSK

JPX Margin Trading Weekly (Jul 25th): Mitsubishi Heavy Industries, Fast Retailing

We analyzed JPX margin trading positions report for the past week and highlighted Mitsubishi Heavy Industries (7011 JP), Fast Retailing (9983 JP),...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)